查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1761526

全球獸醫腫瘤市場評估：依動物類型、療法、癌症類型、地區、機會和預測（2018-2032）

Global Veterinary Oncology Market Assessment, By Animal Type, By Therapy, By Cancer Type, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

全球獸醫腫瘤市場規模預計將從2024年的10.1億美元增至2032年的18.2億美元，在2025-2032年的預測期內，年複合成長率為7.63%。由於寵物老化導致癌症發病率上升、寵物主人 "寵物如家人" 的觀念逐漸形成以及保險公司擴大對複雜手術的承保範圍，該市場呈現快速成長態勢。根據美國獸醫協會的資料，大約四分之一的犬在一生中會罹患癌症，近一半的10歲以上犬會經歷癌症的發作。

獸醫腫瘤學領域致力於癌症的檢測和治療，以及動物癌症的預防策略。獸醫腫瘤科醫師診斷皮膚腫瘤、淋巴瘤和乳房腫瘤等疾病，並以手術合併化療、放療和免疫療法進行治療。該領域的專家將治療方法與疾病的早期發現、適當的分期以及製定個人化治療方案相結合，以取得優異的療效。

寵物醫療照護的改善延長了動物的壽命，也增加了動物癌症診斷的數量。影像技術的改進，以及化療和標靶放射治療方法的改進，使動物癌症治療更加便捷有效。寵物主人現在為他們的寵物尋求專業的醫療服務，因為他們對寵物的健康需求有了更深入的了解，並且擁有足夠的經濟能力來尋求這些服務。製藥業生產多種專門針對動物的癌症治療方法，幫助提高寵物的存活率和生活品質。

例如，2023年11月，TheraVet 專門治療寵物的骨骼和關節疾病。該公司已啟動一項臨床研究，評估BIOCERA-VET骨肉瘤骨水泥成形術合併立體定位放射治療（SRT）對確診患有骨肉瘤的寵物的治療價值。

本報告對全球獸醫腫瘤市場進行了詳細分析，包括市場規模和預測、市場動態以及主要參與者的現狀。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 美國關稅的影響

第4章 執行摘要

第5章 全球獸醫腫瘤市場展望（2018-2032）

  • 市場規模分析及預測
    • 金額
  • 市場佔有率分析及預測
    • 依動物類型
      • 犬科動物
      • 貓科動物
      • 馬科動物
      • 其他
    • 依治療方法
      • 放射療法
      • 手術
      • 化療
      • 免疫療法
      • 其他
    • 依癌症類型
      • 皮膚癌
      • 淋巴瘤
      • 肉瘤
      • 其他
    • 依地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東和非洲
    • 市場佔有率分析：依公司（前五名及其他）（價值）（2024）
  • 市場地圖分析（2024）
    • 依動物類型
    • 依治療方法
    • 依癌症類型
    • 依地區

第6章 北美獸醫腫瘤市場展望（2018-2032）

  • 市場規模分析與預測
    • 金額
  • 市場佔有率分析與預測
    • 依動物類型
      • 犬科動物
      • 貓科動物
      • 馬科動物
      • 其他
    • 依治療方法
      • 放射療法
      • 手術
      • 化療
      • 免疫療法
      • 其他
    • 依癌症類型
      • 皮膚癌
      • 淋巴瘤
      • 肉瘤
      • 其他
    • 各國市場佔有率
      • 美國
      • 加拿大
      • 墨西哥
  • 各國市場評估
    • 美國獸醫腫瘤市場展望（2018-2032）
      • 市場規模分析與預測
      • 市場佔有率分析與預測
    • 加拿大
    • 墨西哥

第7章 歐洲獸醫腫瘤市場展望（2018-2032）

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區獸醫腫瘤市場展望（2018-2032）

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 南美洲獸醫腫瘤市場展望（2018-2032）

  • 巴西
  • 阿根廷

第10章 中東與非洲獸醫腫瘤市場展望（2018-2032）

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 供需分析

第12章 價值鏈分析

第13章 供應鏈分析

第14章 波特五力分析

第15章 PESTLE 分析

第16章 市場動態

  • 市場驅動因素
  • 市場挑戰

第17章 市場趨勢與發展

第18章 監理格局

第19章 個案研究

第20章 競爭格局

  • 五大市場領導者競賽矩陣
  • 五大公司SWOT分析
  • 十大主要公司版圖
    • Zoetis Services LLC
    • Merck & Co. Inc.
    • IDEXX Laboratories, Inc.
    • Heska Corporation
    • Dechra Pharmaceuticals Limited
    • Elanco Animal Health Incorporated
    • Indian Immunologicals Ltd
    • Boehringer Ingelheim International GmbH
    • Hester Biosciences Pvt. Ltd
    • Virbac Animal Health India Private Limited

第21章 策略建議

第22章 關於調查公司及免責聲明

Product Code: MX13548

Global veterinary oncology market is projected to witness a CAGR of 7.63% during the forecast period 2025-2032, growing from USD 1.01 billion in 2024 to USD 1.82 billion in 2032. The veterinary oncology market is experiencing rapid growth due to aging pets experience higher cancer incidence, owners embrace "pet-as-family" mindsets, and insurers broaden coverage for sophisticated procedures. According to the American Veterinary Medical Association, about 1 in 4 dogs experience cancer during their lifespan, and almost half of dogs over the age of 10 will experience cancer development.

The veterinary oncology field specializes in detecting and treating cancer, along with cancer prevention strategies for animals. Veterinary oncologists diagnose diseases including skin tumors, lymphoma, and mammary gland tumors, and use surgery together with chemotherapy and radiation therapy, and immunotherapy for their treatment. Professionals in this specialty deliver superior results by combining therapeutic approaches with early disease detection and proper disease staging, and the development of individualized treatment plans.

The improved medical care of pets leads to extended lifespans and an increased number of cancer diagnoses in animals. The improved imaging technology, together with improved chemotherapy and targeted radiation methods, makes cancer treatment in animals more straightforward and effective. Pet owners now seek special medical attention for their animals because they better understand their pets' health needs, and they have the financial means to pursue it. The pharmaceutical industry produces multiple animal-specific cancer medicines, which lead to improved survival rates, together with enhanced quality of life for pets.

For instance, in November 2023, TheraVet specialized in providing osteoarticular disease treatments for pets. The company has launched a clinical study to assess the therapeutic value of BIOCERA-VET Osteosarcoma Cementoplasty used together with Stereotactic Radiotherapy (SRT) for pets diagnosed with osteosarcoma.

Rising Cancer Prevalence in Animals Boosts Global Veterinary Oncology Market Demand

Animal cancer incidence rates are rising, which drives higher demand for veterinary oncology services. Better healthcare services extend pet lifespans, thus leading to an increased occurrence of age-related cancer cases. The rising number of pet owners and growing animal health awareness generates a strong need for early cancer detection, which results in more screening services and chemotherapy and radiation therapy, along with immunotherapy treatment choices. Modern veterinary clinics use advanced diagnostic equipment and better imaging methods and biopsy procedures to detect cancer earlier while maintaining higher levels of accuracy. Also, pharmaceutical companies advancing targeted therapies for pets drive ongoing market expansion. The veterinary oncology sector achieves rapid progress in treatment alternatives and diagnostic tools due to increasing pet owner investment in premium medical care. Developed regions lead market expansion, which expands globally through infrastructure development in emerging economies, together with rising pet ownership rates.

Additionally, to address the rising cases of cancer in animals and the growing pet ownership, companies are launching new drugs for the treatment of cancer to improve the quality of life. For instance, in March 2025, Privo Technologies Inc. leads as an innovative biopharmaceutical organization that launched BeneVet Oncology to enhance companion animal health. BeneVet utilizes Privo's state-of-the-art drug delivery systems to meet veterinary medical requirements that currently lack solutions.

Technological Advancements in Diagnosis and Treatments Surged Market Growth

The veterinary oncology market is experiencing remarkable growth due to advancements in medical technology for both diagnosis and treatment methods. Modern imaging methods, such as MRI, CT scans, and PET scans, allow precise and early detection in animals. The use of molecular diagnostics and liquid biopsies allows veterinarians to perform non-invasive tumor profiling, which results in better individualized treatment approaches. Targeted drugs work effectively with immunotherapy and monoclonal antibodies to improve patient outcomes and decrease side effects relative to standard chemotherapy approaches. Stereotactic radiosurgery represents the current standard of modern radiation therapy because it allows precise tumor destruction while protecting healthy tissue from harm. The market is experiencing growth because veterinary oncology treatment accessibility improves through telemedicine and AI diagnostic systems. The market expansion receives financial backing through increasing pet populations, together with enhanced knowledge about animal cancer therapy choices. Veterinary research institutes collaborate with pharmaceutical companies that receive regulatory approvals to develop new oncology drugs for their investment. Veterinary oncology receives a market boost from technological and therapeutic advancements, which lead to improved results for both pets and livestock.

For instance, in January 2023, VolitionRx Limited operated as a global epigenetics business that declares its Nu. Q Vet Cancer Test is available for veterinarian pre-orders through Heska Corporation, which delivers rapid, accurate, low-cost, and simple on-site testing solutions to veterinary clinics for improved clinical decisions and better patient results.

Investment in Research and Development Support Market Expansion

Research and development (R&D) investment serves as a fundamental component that expands the veterinary oncology market growth. Pet cancer diagnostics, together with targeted therapies and immunotherapies, are experiencing growth because pharmaceutical companies and academic institutions are increasing their funding. Research and development activities work to produce new treatments while enhancing diagnostic methods and creating better personalized medical approaches for animals with cancer. The increasing number of pet cancer cases, combined with rising pet ownership and increasing veterinary care spending, supports market expansion. The fast development of innovation results from partnerships between veterinary oncologists and biotechnology companies, together with research institutions. The progress of veterinary oncology receives support from government funding and private sector investments, which result in improved treatment outcomes. The veterinary oncology market will experience substantial growth through ongoing R&D development to deliver fresh therapeutic alternatives that enhance animal quality of life. The veterinary cancer research sector needs continuous investment because it generates market growth opportunities for pharmaceutical companies and diagnostic laboratories, and veterinary clinics.

For instance, in January 2024, Morris Animal Foundation announced the selection of eight new grant recipients who advance the Foundation's commitment to improving the lives of dogs suffering from cancer through pioneering research initiatives. The veterinary oncology industry experiences substantial expansion because of ongoing R&D projects, together with industry stakeholder investments during the next several years.

Canine Holds Largest Market Share in Veterinary Oncology

The veterinary cancer market maintains its largest portion through canines because dogs demonstrate a strong cancer tendency that leads to frequent lymphoma, mast cell tumors, and osteosarcoma diagnoses. Advanced diagnostic tools and treatment methods derived from human chemotherapy protocols and stereotactic radiation, and the development of immunotherapy, have increased therapeutic possibilities, which expand the market. The market expansion results from three main factors: longer pet life spans and increased owner funding of specialized cancer treatments, and ongoing research into breed-specific oncogenetics. The field of veterinary oncology benefits from comparative oncology, as canine cancers serve as effective models for human cancers, attracting research funding from both veterinary and biomedical institutions. The veterinary oncology field continues to advance through pharmaceutical innovation, which develops targeted therapies and combination protocols that enhance treatment success, thus making canine oncology a leading veterinary specialty and an expanding sector in animal health.

For instance, in August 2024, Purdue University, together with Akston Biosciences, established a strategic agreement to develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy for canine cancer treatment. The businesses creating immunotherapeutic veterinary cancer therapies contribute to expanding the total market size.

North America Dominates the Veterinary Oncology Market Size

North America dominates the veterinary oncology market due to its large pet population and superior medical facilities, and substantial financial support for animal healthcare. The United States and Canada maintain an advanced veterinary market that operates oncology clinics to provide innovative treatments, including chemotherapy, together with radiation therapy and immunotherapy. The rising awareness of pet cancer and the growing humanization of animals has driven demand for advanced diagnostic procedures and treatment options. High disposable income levels of pet owners enable them to pay for costly medical treatments. The rising number of pet insurance policies enables pet owners to obtain expensive cancer treatment options. North America enjoys strong R&D activities because the leading pharmaceutical companies and academic institutions conduct innovative research on veterinary cancer care. The market expands because of supportive government regulations, together with funding programs dedicated to animal health research. The North American veterinary oncology market leads globally because Zoetis and Elanco serve as major market players. North America continues to dominate the worldwide veterinary oncology market due to multiple factors, which include expanding pet healthcare funding and technological progress.

For instance, in January 2025, IDEXX Laboratories, Inc., introduced IDEXX Cancer Dx as the first lymphoma detection diagnostic panel, which particularly serves the 20 million North American dogs at increased cancer risk. Veterinarians across the United States may now access IDEXX Cancer Dx for USD15, which enables them to add the blood test to sick pet panels or annual wellness screenings and receive actionable results within 2 to 3 days.

Impact of U.S. Tariffs on Global Veterinary Oncology Market

The U.S. tariffs implemented on imported goods, including medical supplies and pharmaceuticals, will create substantial effects on veterinary oncology markets through increased costs for both veterinary clinics and pet owners. Advanced cancer treatments, including radiation therapy machines together with chemotherapy drugs and specialized diagnostics, depend on imported components or finished products that experience tariffs. The increased prices resulting from tariffs will make advanced treatments less affordable, which restricts pet access and slows market expansion. The application of tariffs to protect domestic producers leads to increased manufacturing costs, which forces businesses to raise product prices. Veterinary clinics with constrained budgets choose between postponing equipment upgrades and purchasing lower-quality solutions, which slows down cancer advancement in veterinary medicine. The implementation of tariffs to defend domestic industries generates unforeseen problems that restrict vital animal treatments, thus decreasing the quality of veterinary cancer care across the United States.

Key Players Landscape and Outlook

Industry leaders enhance their position because of technological advancements, together with strategic business relationships and growing market needs. They develop their business through company combinations and worldwide expansion by using research and development to maintain their competitive position. The adoption of artificial intelligence, together with automation and sustainable business practices, helps these organizations protect their future operations. Digital transformation investments, along with customer-centric solutions, create sustainable long-term business expansion. Companies maintain their market strength by developing scalable operations together with adaptable methods and investing in their workforce. They maintain their market leadership by using data-driven choices while building partnerships with other businesses and developing business models that challenge traditional approaches. The future looks promising for businesses that adopt transformation, but they need flexible approaches to maintain their leadership and innovation because of regulatory and economic obstacles.

In September 2024, Boehringer Ingelheim International GmbH finished its purchase of Saiba Animal Health AG to broaden its range of animal therapeutic products. The company's innovative vaccine development platform is expected to enhance the veterinary oncology sector.

In March 2024, Merck & Co. Inc. finished the purchase of Harpoon Therapeutics, Inc., to strengthen our oncology pipeline through cutting-edge solutions that serve cancer patients throughout the world. Following the purchase, Harpoon became a fully owned subsidiary of Merck while its common shares stopped trading on the Nasdaq Stock Market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Oncology Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Animal Type
      • 5.2.1.1. Canine
      • 5.2.1.2. Feline
      • 5.2.1.3. Equine
      • 5.2.1.4. Others
    • 5.2.2. By Therapy
      • 5.2.2.1. Radiotherapy
        • 5.2.2.1.1. Stereotactic Radiation Therapy
          • 5.2.2.1.1.1. LINAC
          • 5.2.2.1.1.2. Other Types
        • 5.2.2.1.2. Conventional Radiation Therapy
      • 5.2.2.2. Surgery
      • 5.2.2.3. Chemotherapy
      • 5.2.2.4. Immunotherapy
      • 5.2.2.5. Others
    • 5.2.3. By Cancer Type
      • 5.2.3.1. Skin Cancers
      • 5.2.3.2. Lymphomas
      • 5.2.3.3. Sarcomas
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Animal Type
    • 5.3.2. By Therapy
    • 5.3.3. By Cancer Type
    • 5.3.4. By Region

6. North America Veterinary Oncology Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Animal Type
      • 6.2.1.1. Canine
      • 6.2.1.2. Feline
      • 6.2.1.3. Equine
      • 6.2.1.4. Others
    • 6.2.2. By Therapy
      • 6.2.2.1. Radiotherapy
        • 6.2.2.1.1. Stereotactic Radiation Therapy
          • 6.2.2.1.1.1. LINAC
          • 6.2.2.1.1.2. Other Types
        • 6.2.2.1.2. Conventional Radiation Therapy
      • 6.2.2.2. Surgery
      • 6.2.2.3. Chemotherapy
      • 6.2.2.4. Immunotherapy
      • 6.2.2.5. Others
    • 6.2.3. By Cancer Type
      • 6.2.3.1. Skin Cancers
      • 6.2.3.2. Lymphomas
      • 6.2.3.3. Sarcomas
      • 6.2.3.4. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Veterinary Oncology Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Animal Type
          • 6.3.1.2.1.1. Canine
          • 6.3.1.2.1.2. Feline
          • 6.3.1.2.1.3. Equine
          • 6.3.1.2.1.4. Others
        • 6.3.1.2.2. By Therapy
          • 6.3.1.2.2.1. Radiotherapy
          • 6.3.1.2.2.1.1. Stereotactic Radiation Therapy
          • 6.3.1.2.2.1.1.1. LINAC
          • 6.3.1.2.2.1.1.2. Other Types
          • 6.3.1.2.2.1.2. Conventional Radiation Therapy
          • 6.3.1.2.2.2. Surgery
          • 6.3.1.2.2.3. Chemotherapy
          • 6.3.1.2.2.4. Immunotherapy
          • 6.3.1.2.2.5. Others
        • 6.3.1.2.3. By Cancer Type
          • 6.3.1.2.3.1. Skin Cancers
          • 6.3.1.2.3.2. Lymphomas
          • 6.3.1.2.3.3. Sarcomas
          • 6.3.1.2.3.4. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Oncology Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Veterinary Oncology Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Veterinary Oncology Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Veterinary Oncology Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Zoetis Services LLC
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Merck & Co. Inc.
    • 20.3.3. IDEXX Laboratories, Inc.
    • 20.3.4. Heska Corporation
    • 20.3.5. Dechra Pharmaceuticals Limited
    • 20.3.6. Elanco Animal Health Incorporated
    • 20.3.7. Indian Immunologicals Ltd
    • 20.3.8. Boehringer Ingelheim International GmbH
    • 20.3.9. Hester Biosciences Pvt. Ltd
    • 20.3.10. Virbac Animal Health India Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 3. Global Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 4. Global Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 5. Global Veterinary Oncology Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 8. North America Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 9. North America Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 10. North America Veterinary Oncology Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 13. United States Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 14. United States Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 15. Canada Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 17. Canada Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 18. Canada Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 19. Mexico Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 21. Mexico Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 22. Mexico Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 23. Europe Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 25. Europe Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 26. Europe Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 27. Europe Veterinary Oncology Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 30. Germany Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 31. Germany Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 32. France Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 34. France Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 35. France Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 36. Italy Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 38. Italy Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 39. Italy Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 40. United Kingdom Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 42. United Kingdom Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 43. United Kingdom Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 44. Russia Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 46. Russia Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 47. Russia Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 48. Netherlands Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 50. Netherlands Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 51. Netherlands Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 52. Spain Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 54. Spain Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 55. Spain Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 56. Turkey Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 58. Turkey Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 59. Turkey Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 60. Poland Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 62. Poland Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 63. Poland Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 64. South America Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 66. South America Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 67. South America Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 68. South America Veterinary Oncology Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 71. Brazil Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 72. Brazil Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 73. Argentina Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 75. Argentina Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 76. Argentina Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 77. Asia-Pacific Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 79. Asia-Pacific Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 80. Asia-Pacific Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 81. Asia-Pacific Veterinary Oncology Market Share (%), By Country, 2018-2032F
  • Figure 82. India Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 84. India Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 85. India Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 86. China Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 88. China Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 89. China Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 90. Japan Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 92. Japan Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 93. Japan Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 94. Australia Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 96. Australia Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 97. Australia Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 98. Vietnam Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 100. Vietnam Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 101. Vietnam Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 102. South Korea Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 104. South Korea Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 105. South Korea Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 106. Indonesia Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 108. Indonesia Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 109. Indonesia Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 110. Philippines Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 112. Philippines Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 113. Philippines Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 114. Middle East & Africa Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 116. Middle East & Africa Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 117. Middle East & Africa Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 118. Middle East & Africa Veterinary Oncology Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 121. Saudi Arabia Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 122. Saudi Arabia Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 123. UAE Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 125. UAE Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 126. UAE Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 127. South Africa Veterinary Oncology Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Veterinary Oncology Market Share (%), By Animal Type, 2018-2032F
  • Figure 129. South Africa Veterinary Oncology Market Share (%), By Therapy, 2018-2032F
  • Figure 130. South Africa Veterinary Oncology Market Share (%), By Cancer Type, 2018-2032F
  • Figure 131. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024